Pipeline

ARGX-112

Target
IL-22R

 

LP0145 (ARGX-112) was designed as a SIMPLE Antibody® to block receptor, IL22R. LEO Pharma is evaluating the antibody for atopic dermatitis.

Pipeline

ARGX-114

Target
MET

AgomAb Therapeutics, a privately held, venture-backed company (www.agomab.com) exclusively licensed the SIMPLE Antibody® technology to generate a set of HGF-mimetic agonists directed at the MET receptor. The lead antibody, AGMB-101 (previously referred to as ARGX-114), has the potential to regenerate damaged tissue in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Pipeline

ARGX-115

Target
GARP

ARGX-115, now known as ABBV-151, was designed as a SIMPLE Antibody® inhibitor of GARP-TGF-β1 and is being investigated by AbbVie for the treatment of cancer. ARGX-115 is designed to block GARP and to reactive the immune system against tumors.

Pipeline

ARGX-116

Target
ApoC3

STT-5058 (ARGX-116) was designed as a SIMPLE Antibody® inhibitor of ApoC3. STT-5058 is a sweeping antibody with recycling properties that are pH-dependent and enable clearing multiple apoC3-containing lipoproteins. Staten is evaluating the antibody for its potential in dyslipidemia management in collaboration with Novo Nordisk.